Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel approach to block HIV-1 coreceptor CXCR4 in non-toxic manner.

Molecular biotechnology - 1 Oct 2014

Liu Ye, Zhou Jieqiong, Pan Ji-An, Mabiala Prudence, Guo Deyin

Abstract excerpt

The chemokine receptor CXCR4 is one of the major coreceptors for human immunodeficiency virus type 1 (HIV-1) and considered as an important therapeutic target. Knockdown of CXCR4 by RNA interference has emerged as a promising strategy for combating HIV-1 infection. However, there is a potential drawback to this strategy as undesired side effects may occur due to the loss of natural function of CXCR4. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotechnology
Share to Genetic Vectors
Share to Lentivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutant Proteins

Share to Receptors, CXCR4

Share to RNA, Small Interfering

Share to Transduction, Genetic

Share to Virus Replication

Source

Identifiers

PMID: 24845753
DOI: 10.1007/s12033-014-9768-7

Genes

CXCR4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel approach to block HIV-1 coreceptor CXCR4 in non-toxic manner.PMID 24845753Read ↗

CXCR4 Is a Potential Target for Anti-HIV Gene TherapySemantic proximity Read ↗

Biomolecular models of EPI-X4 binding to CXCR4 allow the rational optimization of peptides with therapeutic potentialSemantic proximity Read ↗

Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection.Semantic proximity Read ↗

HIV-1 inhibition in cells with CXCR4 mutant genome created by CRISPR-Cas9 and piggyBac recombinant technologiesSemantic proximity Read ↗

Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor.Semantic proximity Read ↗

The biology of CCR5 and CXCR4Semantic proximity Read ↗

Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies.Semantic proximity Read ↗

Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonistsSemantic proximity Read ↗

Development of N-terminally modified variants of the CXCR4-antagonizing peptide EPI-X4 with increased plasma stabilitySemantic proximity Read ↗

RNAi Targeting CXCR4 Inhibits Tumor Growth Through Inducing Cell Cycle Arrest and ApoptosisSemantic proximity Read ↗

Zinc-finger Nuclease Editing of Human cxcr4 Promotes HIV-1 CD4+ T Cell Resistance and EnrichmentSemantic proximity Read ↗

Inhibition of HIV‐1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transductionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.